Skip to main content
Figure 5 | Journal of Hematology & Oncology

Figure 5

From: RETRACTED ARTICLE: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor

Figure 5

EGFR kinase inhibitor gefitinib decreased STS26T MPNST tumor cell proliferation by blocking the PI3K/AKT and MAPK pathways. (A) The IC50 of gefitinib in tumor cells was about 10 μM. (B) At a 10-μM concentration, gefitinib significantly decreased tumor cell proliferation compared with the MOCK and DMSO controls. (C) Gefitinib significantly decreased activation of EGFR. (D) Gefitinib significantly decreased activation of the PI3K/AKT and MAPK signaling pathways. * indicate P-values <0.05.

Back to article page